A practical reference on peptide research: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-05-03 and is reviewed periodically as new material appears.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
carbamazepine, phenytoin gastric acid suppressants: antacids, antimuscarinics, histamine H2 blockers, proton pump inhibitors sucralfate rifampin, rifabutin, isoniazid efavirenz, nevirapine Ritonavir (an antiretrovial medication), is known for increasing the activity of ketoconazole. So it is recommended to reduce dosage. There is also a list of drugs which significantly decrease systemic exposure to the ketoconazole and drugs whose systemic exposure is increased by the ketoconazole.
The two substrates of this enzyme are ribitol and oxidised nicotinamide adenine dinucleotide (NAD+). Its products are D-ribulose, reduced NADH, and a proton. This enzyme participates in pentose and glucuronate interconversions.
Most 1. Bundesliga goals scored: 72 – Vincenzo Grifo 8 May 2026 Highest transfer fee paid: €10 million for Baptiste Santamaria Highest transfer fee received: €60million for Johan Manzambi Youngest goalscorer: Matthias Ginter – 18 years, 2 days Player who has scored the most against club: Claudio Pizarro – 14 goals in 17 matches Biggest home win: 6–0 – against Rot-Weiß Erfurt on 24 August 1991 Biggest 1. Bundesliga home win: 5–0 – against Hansa Rostock on 17 September 1999, against VfL Bochum on 9 December 2000 and against SV Werder Bremen on 21 February 2025 Biggest away win: 6–0 – against Borussia Mönchengladbach on 5 December 2021 Biggest 1. Bundesliga away win: 6–0 – against Borussia Mönchengladbach on 5 December 2021 Biggest home loss: 0–6 – against Bayern Munich on 16 December 2003 and against Werder Bremen on 4 December 2004 and 21 November 2009 Biggest 1. Bundesliga home loss: 0–6 – against Bayern Munich on 16 December 2003 and against Werder Bremen on 4 December 2004 and 21 November 2009 Biggest away loss: 0–7 – against Bayern Munich on 10 September 2011 Biggest 1. Bundesliga away loss: 0–7 – against Bayern Munich on 10 September 2011
== Safety and the environment == Indigo has a low oral toxicity, with an LD50 of 5 g/kg (0.5% of total mass) in mammals. In 2009, large spills of blue dye were reported downstream of a blue jeans manufacturer in Lesotho. The compound has been found to act as an agonist of the aryl hydrocarbon receptor.
=== Ancient history === There have been reports of stupor-like and catatonia-like states in people throughout the history of psychiatry. In ancient Greece, the first physician to document stupor-like or catatonia-like states was Hippocrates, in his Aphorisms. He never defined the syndrome, but seemingly observed these states in people he was treating for melancholia. In ancient China, the first descriptions of people that appear in the Huangdi Neijing (The Yellow Emperor's Inner Canon), the book which forms the basis of Traditional Chinese Medicine. It is thought to have been compiled by many people over the course of centuries during the Warring States Period (475-221 BCE) and the early Han Dynasty (206 BCE-220 CE).
Sources: en.wikipedia.org
==== Places ==== In 2012, Doillon signed her first recording deal for three albums with Barclay (Universal Music France). Her first EP I.C.U came out in June and was produced by Étienne Daho and mixed by Philippe Zdar from the band Cassius. Doillon's first album was recorded in France over a 15 day period in the Studio La Seine with French musicians François Poggio, Marcello Guliani, Alexis Anérilles and Philippe Entressangle. Her debut album Places reached number three on the French charts. It also reached number one on Canadian iTunes, number two on French iTunes and was released through Verve in the US and decca in the UK. The artwork for the cover was done by Inez and Vinoodh. Doillon was on the cover of influential magazines Magic, Telerama and Les Inrockuptibles. The first single, "I.C.U", was followed by a video directed by Antoine Carlier, reconstituting her wanderings through Paris. Then came "Questions and Answers" directed by Gaetan Chataigner while Doillon was on tour and "Devil or Angel" directed by Christophe Acker in Scotland. In October 2012, Doillon started her first tour at French rock club La Flèche d'Or and played France, Belgium, Germany, Switzerland, Canada and England. This tour also played at Paris's Le Trianon venue. On 8 February 2013, during the Victoires de la musique ceremony (French equivalent of the Grammy's) at the Zenith of Paris, she was awarded Best Female Performer of the Year, competing alongside prestigious artists such as Françoise Hardy and Celine Dion. It was the first time a newcomer English-speaking performer won in that category.
== Emulsifiers == Lecithins, monoglycerides, diglycerides, and DATEM are considered emulsifiers. They disperse fat more evenly throughout the dough, helping it to trap more of the carbon dioxide bubbles produced by yeast. Lecithin added at a rate of 0.25-to-0.6% of the flour weight acts as a dough conditioner. Liquid soy lecithin may be used at a rate of up to 2% of the fat weight. It may be preferred to base the percentage on fat because lecithin dissolves well in warm fats. Based on total weight, egg yolk contains about 9% lecithin. Monoglycerides and diglycerides replace egg lecithin in baked goods. Emulsifiers have antistaling effects and tend to produce a finer grain, softer crumb, and with longer proof times, increased baked volumes.
RNA World website Link collection (structures, sequences, tools, journals) Nucleic Acid Database Images of DNA, RNA, and complexes. Anna Marie Pyle's Seminar: RNA Structure, Function, and Recognition Archived 2018-06-21 at the Wayback Machine
Around 2009, Japanese military strategist Toshi Yoshihara and Naval War College professor James R. Holmes suggested the American military could exploit the geography of the first island chain to counter the People's Liberation Army Navy build-up. The Cabinet of Japan has also passed defense white papers emphasizing the threat posed by the People's Liberation Army Navy in the first island chain. In the later years of the 2010s, Japan started deploying military assets to Yonaguni and its other islands to counter China's presence along that area of the first island chain. Japan's strategic position in the first island chain began with US-Japan joint efforts to counter Soviet expansion. The Japan Self-Defense Forces currently plays the role of protecting US military bases and preserving military strength in East Asia. As for Japan's Territorial Protection Self-Defense Forces, which mainly rely on islands in southern Japan adjacent to the Yellow Sea and the East China Sea, Japan has military advantages in anti-submarine, air defense and sea mine technologies. In 2026, Japan and the US agreed to expand joint military training across the first island chain.
== External links == Isotopic effect Measurement In sugar solutions Why measure water activity? at the Wayback Machine (archived 2020-08-07) How to measure water activity? at the Wayback Machine (archived 2020-08-07)
Sources: en.wikipedia.org
phytate), disease and metabolic disorders (e.g. environmental enteric dysfunction), the reproductive cycle, quantity of mineral in diet, chronic mineral deficiency, subject age and homeostatic mechanisms. When results from such studies are available for a mineral, they may serve as a basis for estimations of the human physiological and dietary requirements of the mineral. When tracer is administered with food for the purpose of observing mineral absorption and metabolism, it may be in the form of an intrinsic or extrinsic label. An intrinsic label is isotope that has been introduced into the food during its production, thus enriching the natural mineral content of the food, whereas extrinsic labeling refers to the addition of tracer isotope to the food during the study. Because it is a very time-consuming and expensive approach, intrinsic labeling is not routinely used. Studies comparing measurements of absorption using intrinsic and extrinsic labeling of various foods have generally demonstrated good agreement between the two labeling methods, supporting the hypothesis that extrinsic and natural minerals are handled similarly in the human gastrointestinal tract. Enrichment is quantified from the measurement of isotope ratios, the ratio of the tracer isotope to a reference isotope, by mass spectrometry. Multiple definitions and calculations of enrichment have been adopted by different researchers. Calculations of enrichment become more complex when multiple tracers are used simultaneously. Because enriched isotope preparations are never isotopically pure, i.e.
Lyse the cells or tissue and isolate the mRNA molecules bound to ribosomes. Immobilize complexes. This is commonly performed with cycloheximide but other chemicals can be employed. It is also possible to forgo translation inhibitors with translation-incompetent lysis conditions. Using ribonucleases, digest the RNA not protected by ribosomes. Isolate the mRNA-ribosome complexes using sucrose gradient density centrifugation or specialized chromatography columns. Phenol/chloroform purification of mixture to remove proteins. Size-select for previously-protected mRNA fragments. Ligate 3' adapter to fragments. Reverse transcribe RNA to cDNA using reverse transcriptase. Circularize the cDNA Subtract known rRNA contaminants (optional). Amplify in strand-specific manner. Sequence reads. Align sequence results to genomic sequence to determine translational profile. Analyze resulting data using computational approaches specifically designed for ribosome profiling.
Parasitic infections include trichomoniasis, pediculosis pubis, and scabies. Trichomoniasis is transmitted by a parasitic protozoan and is the most common non-viral STI. Most cases are asymptomatic but may present symptoms of irritation and a discharge of unusual odor. Pediculosis pubis, commonly called crabs, is a disease caused by the crab louse an ectoparasite. When the pubic hair is infested, the irritation produced can be intense. Scabies, also known as the "seven year itch", is caused by another ectoparasite, the mite Sarcoptes scabiei, giving intense irritation.
From May 1991 to the end of the year, the EPRDF is suspected to have committed dozens of summary executions despite the government's lack of information surrounding state-sanctioned executions. The 1992 elections for 14 new regional assemblies were widely criticized by international observers who asserted that instances of fraud and the arrests of opposition leaders rendered the elections' results, which overwhelmingly favored the EPRDF, meaningless. For instance, in many cases, candidates representing the All-Amhara People's Organization were prevented from registering themselves in various constituencies. Similarly, candidates representing the Oromo Liberation Front (OLF) were threatened, harassed, and detained by the EPRDF. Despite a law that lifted nearly all of the censorship restrictions enacted by the PDRE, much of the media was still controlled by the government and many journalists were still reluctant to risk challenging the TGE or raising awareness of the regime's abuses. Later, the TGE created a Special Prosecutor's Office to begin investigating government personnel associated with the previous regime or Mengistu's Worker's Party of Ethiopia, deciding to formally suspend habeas corpus from August 1992 to the end of the year. By the end of the year, however, none of the detainees had been charged with any crimes.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.